Adams v. Mass General Brigham Incorporated

CourtDistrict Court, D. Massachusetts
DecidedSeptember 28, 2023
Docket1:21-cv-11686
StatusUnknown

This text of Adams v. Mass General Brigham Incorporated (Adams v. Mass General Brigham Incorporated) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Adams v. Mass General Brigham Incorporated, (D. Mass. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

_______________________________________ ) TYLER ADAMS, et al., ) ) Plaintiffs, ) ) Civil Action No. v. ) 21-11686-FDS ) MASS GENERAL BRIGHAM ) INCORPORATED, ) ) Defendant. ) _______________________________________)

MEMORANDUM AND ORDER ON DEFENDANT’S MOTION FOR SUMMARY JUDGMENT

SAYLOR, C.J. This is a dispute arising from a mandatory COVID-19 vaccination policy at a major hospital network. Defendant Mass General Brigham Incorporated (“MGB”) adopted a policy in June 2021 that required all of its employees to be vaccinated against COVID-19, with provisions for medical or religious exemptions under certain circumstances. More than 2,400 employees applied for exemptions; MGB granted only 234. Plaintiffs here are 160 of those employees who were denied exemptions. The complaint alleges violations of the Americans with Disability Act, 42 U.S.C. § 12101 et seq., and Title VII of the Civil Rights Act, 42 U.S.C. § 2000e et seq. After the first phase of discovery, MGB has moved for summary judgment on both the ADA and Title VII claims as to all plaintiffs. It contends that there is no genuine dispute of material fact that accommodating plaintiffs would be an undue hardship, and that plaintiffs cannot establish a prima facie case under the ADA as a matter of law. This aspect of the dispute does not directly involve the legality of the vaccination policy itself, but whether accommodating any additional employees would constitute an “undue hardship” to MGB. Nonetheless, the context in which the policy was adopted is significant. As a major hospital and healthcare system, MGB is unquestionably entitled to rely on its own medical and scientific judgment in matters of patient health and safety, and to adopt strict

infection-control policies to protect its patient and staff populations. And it has a strong interest in maintaining public confidence in the safety of its facilities. It is also true that substantial deference must be given to the judgments of a hospital organization struggling to cope with a worldwide pandemic. And it is emphatically not the role of the federal courts simply to second-guess those judgments, or to substitute its own views for those of trained medical personnel. In short, MGB was entitled to make a medical and scientific judgment as to the safety and efficacy of the COVID-19 vaccines, and to determine whether a mandatory vaccination policy was appropriate. It was not required to permit its staff to take unnecessary risks with patient health and safety. Nor was it required to accommodate irrational fears or conspiracy

theories. Indeed, it is possible that MGB could have reasonably concluded that all of its employees should be vaccinated, without exception, and to have adopted a zero-tolerance policy toward those who refused to do so. Instead, however, MGB set up a process under which a relative handful of employees were granted exemptions from the vaccination requirement on religious or medical grounds, and permitted to continue to work while wearing masks. It thus effectively made a determination that some level of risk—eventually, involving 234 unvaccinated individuals out of approximately 93,600 employees—was tolerable. MGB now contends that permitting 160 additional employees to remain unvaccinated would impose an “undue hardship” within the meaning of federal law due to the additional risk that those persons would present. It characterizes that additional risk as exponential, rather than merely incremental. However, even assuming the truth of that assertion—and even assuming that the adoption of the vaccination policy was entirely appropriate and lawful—it does not

follow that summary judgment can be granted as to the claim of every plaintiff in this lawsuit. This dispute does not involve an all-or-nothing proposition, in which the Court is required to conclude either that all 160 employees must be granted exemptions, or none of them. MGB made a series of separate exemption decisions as to each plaintiff. The complete factual context in which those decisions were made is not presently before the Court. It is possible, of course, that every one of those decisions was entirely defensible, indeed correct. But it is also possible that some subset of those decisions, even a single one, was improper. And the Court cannot conclude, at least on this record, that the additional risk—which could, conceivably, arise out of a differential between 234 and 235 unvaccinated employees—warrants the entry of summary judgment in MGB’s favor in the aggregate as to every claim.

The claims of six specific plaintiffs, however, are on a different footing. As to each of those claims, MGB has established that the undisputed facts—for example, the failure of a plaintiff to offer proof of a medical condition—warrant the entry of summary judgment. Accordingly, and for the following reasons, MGB’s motion for summary judgment will be granted in part and denied in part. I. Background A. Factual Background The following facts are undisputed unless noted otherwise. 1. The Parties MGB is a major health-care system comprising multiple institutions, including Massachusetts General Hospital, Brigham and Women’s Hospital, and Massachusetts Eye and Ear Infirmary. (Gilbreth Decl. ¶ 5, Def.’s App’x, Vol. I at 78; Pls.’ SMF ¶ 1). MGB employs 6,500 physicians, 9,100 nurses, and 78,000 other workers. (Klompas Decl. ¶ 5, Def.’s App’x, Vol. I at 24). It provides care for 1.5 million patients annually, including “some of the most

complicated and vulnerable patients in the world.” (Id. ¶ 6; Pls.’ SMF ¶ 2). Plaintiffs are 160 former employees of MGB. (See generally, Def.’s App’x, Vol. V).1 They worked in various capacities at MGB, including roles that directly provided medical care or assistance to patients. (See Chart D, Def.’s App’x, Vol. IV at 7-10; Pls.’ SMF ¶ 259).2 Other plaintiffs worked in direct proximity to patients and staff. (E.g., Erickson Dep. at 101, Def.’s App’x, Vol. III at 131).3 Of the 21 plaintiffs who contend that their work was remote, 17 acknowledge that they had been on-site at an MGB entity at least once since January 1, 2019. (See Chart C, Def.’s App’x, Vol. IV at 5-6; Pls.’ SMF ¶ 261). 2. COVID-19 COVID-19 is a contagious viral disease that can cause serious illness and death. As of this writing, more than 1.1 million people in the United States have died from COVID-19. CTRS.

FOR DISEASE CONTROL AND PREVENTION, PROVISIONAL DEATH COUNTS FOR COVID-19 (2023) (last updated September 13, 2023). COVID-19 is particularly dangerous for the elderly, and for people with lung conditions; heart disease; brain and nervous system conditions; diabetes;

1 Plaintiffs’ corrected amended complaint included 223 plaintiffs. (ECF No. 61). Of those, 47 plaintiffs voluntarily dismissed their claims (ECF Nos. 70, 73, 76, 89, 96, 97, 139); 15 plaintiffs were dismissed for failure to prosecute (ECF No. 99); and one plaintiff was dismissed as a sanction for failure to make discovery (ECF No. 140). (See also Def.’s Mem. at 18 n.7). 2 The Court cites MGB’s summaries of the discovery questionnaire responses for convenience. The questionnaire responses are in Volume V of MGB’s appendix to its motion for summary judgment. 3 For example, plaintiff Christopher Erickson “occasionally” visited the oncology inpatient floors in his capacity as a clinical business analyst, walking around patients with cancer and undergoing chemotherapy. (Erickson Dep. at 101, Def.’s App’x, Vol. III at 131). obesity; cancer; certain blood disorders; a weakened immune system; chronic kidney or liver diseases; and Down syndrome.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Trans World Airlines, Inc. v. Hardison
432 U.S. 63 (Supreme Court, 1977)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
School Bd. of Nassau Cty. v. Arline
480 U.S. 273 (Supreme Court, 1987)
Navarro Pomares v. Pfizer Corporation
261 F.3d 90 (First Circuit, 2001)
Cloutier v. Costco Wholesale Corp.
390 F.3d 126 (First Circuit, 2004)
Mulloy v. Acushnet Company
460 F.3d 141 (First Circuit, 2006)
Milissa Garside v. Osco Drug, Inc.
895 F.2d 46 (First Circuit, 1990)
Samuel Mesnick v. General Electric Company
950 F.2d 816 (First Circuit, 1991)
Patrick J. O'COnnOr v. Robert W. Steeves
994 F.2d 905 (First Circuit, 1993)
Ramos-Echevarria v. Pichis, Inc.
659 F.3d 182 (First Circuit, 2011)
Zenaida Garc A-Ayala v. Lederle Parenterals, Inc.
212 F.3d 638 (First Circuit, 2000)
Jones v. Walgreen Co.
679 F.3d 9 (First Circuit, 2012)
Jones v. Nationwide Life Insurance
696 F.3d 78 (First Circuit, 2012)
Kassi Tchankpa v. Ascena Retail Group, Inc.
951 F.3d 805 (Sixth Circuit, 2020)

Cite This Page — Counsel Stack

Bluebook (online)
Adams v. Mass General Brigham Incorporated, Counsel Stack Legal Research, https://law.counselstack.com/opinion/adams-v-mass-general-brigham-incorporated-mad-2023.